<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01198054</url>
  </required_header>
  <id_info>
    <org_study_id>LENA-LMA-5</org_study_id>
    <nct_id>NCT01198054</nct_id>
  </id_info>
  <brief_title>LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>PILOT STUDY PHASE II, Multicenter, Non-randomized, TO ASSESS THE EFFICACY AND SAFETY OF LENALIDOMIDE IN INDUCTION AND POST-INDUCTION IN PATIENTS WITH NOVO Acute Myeloid Leukemia (AML) WITH Cytogenetic Abnormality Monosomy 5</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of post-induction lenalidomide in&#xD;
      patients with de novo AML with deletion 5q cytogenetic abnormality (del (5q)) or monosomy 5&#xD;
      (-5), who obtained complete remission after conventional induction chemotherapy. So, too, for&#xD;
      those who no obtained response treatment (total resistance) or partial remission.&#xD;
&#xD;
      At the same time, the study evaluate the security of lenalidomide.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectivity: Duration of response with lenalidomide after conventional induction chemotherapy</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate the effectiveness of post-induction lenalidomide in patients with de novo AML with deletion 5q cytogenetic abnormality (del (5q)) or monosomy 5 (-5), who obtained complete remission after conventional induction chemotherapy. So, too, for those who no obtained reponse treatment (total resistance) or partial remission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability: Type and intensity of adverse events related with lenalidomide</measure>
    <time_frame>1 year</time_frame>
    <description>Type and intensity of adverse events related with lenalidomide</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>AML</condition>
  <arm_group>
    <arm_group_label>Lenalidomine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Post-induction lenalidomide in patients with de novo AML with deletion 5q cytogenetic abnormality (del (5q)) or monosomy 5 (-5)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Initial dose of oral lenalidomide is 10 mg/day for 28 days every 28 days, during 6 months.&#xD;
In case of response on day 169, patient will follow a treatment extension phase. The dose of lenalidomide should be the same as the last dose for initial phase, until 24 months or progression disease</description>
    <arm_group_label>Lenalidomine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirm the diagnosis of AML according to WHO criteria (Annex 4).&#xD;
&#xD;
          2. AML de novo (ie, patients without documented history of previous treatment with&#xD;
             antineoplastic agents for radiotherapy or other oncological diseases, hematological or&#xD;
             immunological, related to the development of secondary LMAs and secondary AML patients&#xD;
             without primary MDS with del (5q) or -5 [documented history of primary MDS with&#xD;
             transformation to LMAs]).&#xD;
&#xD;
          3. Diagnostic confirmation of the abnormality del (5q) or -5, with or without other&#xD;
             cytogenetic abnormalities. It is not necessary that the del (5q) including band 5q31.&#xD;
&#xD;
          4. Patients who have received one cycle of induction chemotherapy consisting of a&#xD;
             classical combination of anthracycline and cytarabine (with or without etoposide as a&#xD;
             third agent associated), regardless of the response.&#xD;
&#xD;
          5. Patients have been evaluated the response to induction chemotherapy with&#xD;
             anthracyclines and cytarabine (with or without etoposide as third agent partner) and&#xD;
             were classified according to the criteria of IWG.20&#xD;
&#xD;
          6. ≤ 60 patients ineligible for allogeneic hematopoietic progenitors.&#xD;
&#xD;
          7. Patients&gt; 60 years are not eligible for allogeneic hematopoietic stem cell, or&#xD;
             eligible but did not have HLA-identical brother.&#xD;
&#xD;
          8. Accept the use of any contraceptive method effective in patients of childbearing age&#xD;
             with reproductive potential (see Section 6.5 on pregnancy prevention plan).&#xD;
&#xD;
          9. Ability to understand and voluntarily sign informed consent form.&#xD;
&#xD;
         10. Age ≥ 18 years at the time of signing the informed consent form.&#xD;
&#xD;
         11. Ability and willingness to follow the schedule of study visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. AML secondary to treatment with cytostatic or immunosuppressive agents,&#xD;
             myelodysplastic syndrome or other neoplastic disease.&#xD;
&#xD;
          2. AML with cytogenetic abnormalities t (15, 17), t (8; 21), t (16; 16) or inv (16) or&#xD;
             their associated molecular rearrangements.&#xD;
&#xD;
          3. Patients who have received remission induction with a different regime to cytarabine&#xD;
             anthracycline / - etoposide.&#xD;
&#xD;
          4. ≤ 60 patients eligible for allogeneic hematopoietic progenitors.&#xD;
&#xD;
          5. Patients&gt; 60 years eligible for allogeneic hematopoietic stem cell transplant and who&#xD;
             have HLA-identical brother.&#xD;
&#xD;
          6. Patients who have not been evaluated the response to induction chemotherapy (complete&#xD;
             remission, partial remission or resistance (see Table 6).&#xD;
&#xD;
          7. ECOG 3-4.&#xD;
&#xD;
          8. Any of the following laboratory abnormalities Serum creatinine&gt; 2.0 mg / dl (177 mmol&#xD;
             / l). serum aspartate aminotransferase (AST) / glutamic oxalacetic transaminase serum&#xD;
             (SGOT) or alanine aminotransferase (ALT) / serum glutamate pyruvate transaminase&#xD;
             (SGPT)&gt; 5.0 x upper limit of normal (ULN).&#xD;
&#xD;
             total serum bilirubin&gt; 3 mg / dl.&#xD;
&#xD;
          9. Patient with known positive HIV serology. No HIV test is required in the process of&#xD;
             selection.&#xD;
&#xD;
         10. Any severe psychiatric condition or disease that prevents the patient sign the&#xD;
             informed consent form for the patient or involves an unacceptable risk should&#xD;
             participate in the study.&#xD;
&#xD;
         11. Any serious organic disease or condition that behave for the patient if an&#xD;
             unacceptable risk to participate in the study.&#xD;
&#xD;
         12. Previous use of cytotoxic chemotherapy agents or experimental agents (agents are not&#xD;
             commercially available) for the treatment of AML.&#xD;
&#xD;
         13. Pregnant or breastfeeding (see Section 6.5 on pregnancy prevention plan).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanz Miguel, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>PETHEMA Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General de Alicante.</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico y Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Juan Canalejo.</name>
      <address>
        <city>La Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos de Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal. Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central de Asturias.</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Salamanca.</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío.</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>July 29, 2010</study_first_submitted>
  <study_first_submitted_qc>September 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2010</study_first_posted>
  <last_update_submitted>April 4, 2014</last_update_submitted>
  <last_update_submitted_qc>April 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>Lenalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

